Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

No phase data

Trial Status

Other2

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT06045585Early Phase 1Unknown
JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma
Relapsed or Refractory B-cell Lymphoma
PrincipalinvestigatorStart date: 2023-08-18
NCT06298266Early Phase 1Not Yet Recruiting
To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Affiliations

Guangdong Second Provincial General Hospital

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Yang Xiao, MD

Shenzhen Nanshan District Shekou People's Hospital

Related
1 trials

Shared therapeutic areas:

Relapsed or Refractory Multiple Myeloma
Similarity Score15%

Zhitao Ying, MD

Peking University Cancer Hospital & Institute

Related
1 trials

Shared therapeutic areas:

Relapsed or Refractory B-cell Lymphoma
Similarity Score15%

Gang An

Institute of Hematology & Blood Diseases Hospital Ethics Committee

Related
1 trials

Shared therapeutic areas:

Relapsed or Refractory Multiple Myeloma
Similarity Score15%

Marc S. Raab, PD Dr. med.

Medizinische Klinik V, University Hospital Heidelberg

Related
1 trials

Shared therapeutic areas:

Relapsed or Refractory Multiple Myeloma
Similarity Score15%

Jin Lu, PhD

Peking University People's Hospital

Related
2 trials

Shared therapeutic areas:

Relapsed or Refractory Multiple Myeloma
Similarity Score15%

Sven Gogov, MD

Incyte Corporation

Related
3 trials

Shared therapeutic areas:

Relapsed or Refractory Multiple Myeloma
Similarity Score15%

Ravi Vij, M.D.

Washington Universtiy in St. Louis

Related
1 trials

Shared therapeutic areas:

Relapsed or Refractory Multiple Myeloma
Similarity Score15%

Weili Zhao, PhD, MD

Ruijin Hospital

Related
2 trials

Shared therapeutic areas:

Relapsed or Refractory B-cell Lymphoma
Similarity Score15%

Martin Kaiser

Institute of Cancer Research, United Kingdom

Related
1 trials

Shared therapeutic areas:

Relapsed or Refractory Multiple Myeloma
Similarity Score15%

Jianmin luo, PhD&MD

The Second Hospital of Hebei Medical University

Related
4 trials

Shared therapeutic areas:

Relapsed or Refractory Multiple Myeloma
Similarity Score15%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT06045585Early Phase 1PrincipalInvestigator

JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma

Relapsed or Refractory B-cell Lymphoma
Unknown
NCT06298266Early Phase 1PrincipalInvestigator

To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma
Not Yet Recruiting

All 2 trials loaded